Gradientech at ESCMID Global 2025
The diagnostics company Gradientech announces the presentation of new study data from clinical, real-world evaluations with its QuickMIC® system for ultra-rapid antibiotic susceptibility testing (AST) at ESCMID Global 2025 in Vienna, Austria, April 11th-15th.
ESCMID Global, organised by ESCMID – European Society of Clinical Microbiology and Infectious Diseases, is one of the most comprehensive and influential congresses in infectious diseases and microbiology, bringing together over 16,000 professionals worldwide.
Gradientech presents three abstracts, highlighting new clinical data from QuickMIC® studies in both low and high-resistance settings, including results on rapid AST for patients with urosepsis and rapid AST results for cefiderocol – an antibiotic that has posed a challenge for traditional AST systems. An additional abstract by Padua University Hospital in Italy presents a comparison of the performance of QuickMIC and traditional AST testing.
“We are proud to have a significant number of QuickMIC studies being presented at ESCMID Global also this year. In addition we will showcase the latest version of the QuickMIC system with an integrated screen solution that will reduce the footprint to a minimum in our users’ labs. All this gives us a golden opportunity to highlight and show how QuickMIC with precise MIC values, ultra-rapid test times and a minimum footprint can advance AST diagnostics to the next level,” says Sara Thorslund, CEO and co-founder at Gradientech. “ESCMID Global is truly an international hub where leading experts, clinicians and microbiologists gather to exchange valuable insights to advance the field.”
Discover QuickMIC® at ESCMID Global 2025
April 11th-15th
Messe Wien Exhibition & Congress Center, Vienna
Gradientech Booth E36, Exhibition Hall
|
Abstract title |
Presentation details |
|
Rapid AST for patients with suspected urosepsis: optimised sample management to reduce time to guide antibiotic therapy Rolf M et al. |
Poster session, P1510 |
|
Unlocking rapid phenotypic AST direct-from-blood with automated microbial detection and quantitative growth monitoring Lockhart D et al. |
Poster session, P1439 Date: April 14 Time: 12:00 |
|
Rapid susceptibility testing of cefiderocol directly from positive blood cultures using a microfluidic agar-diffusion assay Åman A et al. |
Poster session, P1550
|
|
Rapid antimicrobial resistance diagnosis in sepsis: a comparative study of a microfluidic rapid AST system and broth microdilution on Gram-negative pathogens Di Sopra S et al. |
Poster session, P1513 Time: 12:00 |
The ultra-rapid and precise antibiotic susceptibility testing results of QuickMIC® contribute to timely and effective management of sepsis patients, helping clinicians make faster antibiotic treatment decisions. Its modular design offers affordable scaling possibilities, making QuickMIC suitable for both small and large hospital laboratories. QuickMIC and its gram-negative panel are CE marked and commercially available in Europe but not yet available for sale in the United States.
For further information, please contact:
Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
About Gradientech
Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, contributes to the effective management of sepsis patients by supporting antibiotic treatment decisions in record time. This helps save lives, reduce healthcare costs, and combat the spread of antibiotic resistance – one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.